{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"}],"units":"Participants"}],"description":"Overall event-free survival (EFS) was defined as the time from study enrollment to induction failure, relapse, secondary malignancy, death, or study withdrawal for any reason, with event-free patients censored on the date of the last follow-up","groups":[{"description":"Evaluation of all study participants","id":"OG000","title":"Overall"}],"paramType":"NUMBER","populationDescription":"238 patients were enrolled on the study. Out of 238, 6 were determined to be ineligible and 2 were not randomized. Of the 230 patients, 14 bi-phenotypic leukemia patients were excluded. 216 AML patients were included to estimate EFS.","reportingStatus":"POSTED","timeFrame":"Five Year","title":"To Estimate the Overall Event-free Survival (EFS) of AML Patients Who Undergo Risk-adapted and Genotype-directed Therapy","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}